Navigation Links
Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
Date:12/19/2007

FDA Offers Special Protocol Assessment for Reviroc

AMSTERDAM, December 19 /PRNewswire/ -- Kiadis Pharma announced today that it has successfully completed an End of Phase II meeting for Reviroc with the U.S. Food and Drug Administration (FDA). Reviroc is under development for elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients. The FDA agreed that the data from the completed phase II clinical Reviroc trial is sufficient to support the start of a phase III study. The FDA offered Kiadis Pharma its Special Protocol Assessment (SPA) procedure allowing Kiadis Pharma to work directly with the FDA to optimize the clinical design of the trial.

The FDA meeting followed the successful completion of a multi centre phase II study for Reviroc showing an improved overall survival after autologous bone marrow transplantation in Non-Hodgkin's lymphoma patients. The phase III clinical trial design for Reviroc will focus on patients with Large B cell lymphoma. Kiadis Pharma anticipates filing of the IND, SPA request and Orphan Drug Designation application with the FDA within the next few weeks.

"We are very pleased with the outcome of the End of Phase II meeting with the FDA and with the possibility to access the FDA's Special Protocol Assessment program. Together with the strong support by our principal investigators we are well prepared to design a clear path towards marketing authorization for Reviroc," said Manja Bouman, CEO Kiadis Pharma.

About Reviroc

Reviroc is being developed as a treatment that eliminates blood cancer cells from autologous transplants for patients with end stage blood cancer. An autologous transplant uses the patient's own bone marrow to serve as a graft. Bone-marrow transplants are broadly recognized as a treatment option for patients suffering from blood cancers, such as leukemia and lymphoma. One of the limitations of autologous bone mar
'/>"/>

SOURCE Kiadis Pharma
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... N.C. and PARIS ... firm AgBiome, and Genective, key developer of biotech ... the discovery of new generations of insect control ... insect control to counter the realities of advancing ... Genective, aligning AgBiome,s unique insect control technology with ...
(Date:7/1/2015)... July 1, 2015   Decision Resources Group ... advantages of Otezla are its oral administration, alternative ... reported by surveyed rheumatologists. Otezla was the first ... treatment of active psoriatic arthritis in ... of care includes conventional oral treatments including disease-modifying ...
(Date:7/1/2015)... , ... July 01, 2015 , ... The next-generation sequencing ... key market segments, including the molecular diagnostics industry. BCC Research reveals in its new ... NGS-based tests, lower test costs, and a growing need for better diagnostics as part ...
(Date:7/1/2015)... India , July 1, 2015  Strand Life ... generation sequencing technology to empower cancer care, today announced ... chief executive officer. In his expanded role as now ... strategy, business expansion and worldwide operations effective immediately.  Dr. ... chairman and CEO since its founding in 2000, will ...
Breaking Biology Technology:AgBiome and Genective collaborate to create novel insect-resistant crops 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3
... (NYSE AMEX: IBIO) announced today the pricing of an ... for gross proceeds of approximately $10 million.  Each unit consists ... warrant to purchase one share of common stock.  The warrants ... be exercisable beginning one year and one day from the ...
... 10, 2012 Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) today ... 10:45 am (PST) in the Windsor Room of the Sir ... SF 2012 Conference for emerging biotech companies held over 3 ... Conference.  Over one thousand attendees are expected to be listening ...
... $650,000 awarded to Innovative Libraries, New Scholars and Nurse Faculty ... the 2011 grant recipients for the Innovative Libraries in Developing ... been committed to nine institutions around the world in addition ...  The Elsevier Foundation is funded by Elsevier , a ...
Cached Biology Technology:iBio, Inc. Prices $10 Million Public Offering 2iBio, Inc. Prices $10 Million Public Offering 3iBio, Inc. Prices $10 Million Public Offering 4NW Bio to Present Today at the OneMedForum SF 2012 Conference 2NW Bio to Present Today at the OneMedForum SF 2012 Conference 3Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries 2Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries 3Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries 4Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries 5Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries 6Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries 7Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries 8Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries 9Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries 10
(Date:6/30/2015)... June 30, 2015 To bolster its efforts and ... Corp. announced today the addition of two new team members. ... board advisor and David Raviv will act as ... HYPR Corp.,s commitment to providing the most secure solutions for ... co-founded Layer 7 Technologies, a provider of security and ...
(Date:6/30/2015)... June 30, 2015 Genisphere announced ... CEO to help further develop Genisphere,s therapeutics capabilities and ... experience, having spent much of the last 25 years ... Baxter Bioscience, and Johnson & Johnson. Tom started his ... and Biotech Corporate Finance. He graduated from Dartmouth College ...
(Date:6/29/2015)... June 24, 2015 Research ... the "Latin America Biomedical Sensors Market - Growth, ... The Latin America Biomedical Sensors market is ... of 2.04% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... JISC Collections has purchased the archive content of ... protocols. With immediate effect the SpringerProtocols archive content ... of charge to UK Higher and Further Education ... than 31,000 protocols, most of which come from ...
... , May 2, 2013 CDX Diagnostics, Inc ... ), filed a patent infringement action against Histologics, LLC, ... Pathology, LLP d/b/a Avero Diagnostics (collectively, "Defendants") in the ... New York . According to court ...
... New discoveries of the way plants transport important substances ... pests, increase salt and drought tolerance, control water loss ... the supply of food and energy for our rapidly ... 12 leading plant biologists from around the world whose ...
Cached Biology News:JISC Collections purchases SpringerProtocols 2Shared Medical Resources, LLC files suit against Histologics, LLC, Women's Health Laboratories and Avero Diagnostics for Willful Patent Infringement 2New plant protein discoveries could ease global food and fuel demands 2New plant protein discoveries could ease global food and fuel demands 3New plant protein discoveries could ease global food and fuel demands 4
... emerging as a powerful new tool for ... only amino groups have been able to ... as our Sulfo-SBED. Sulfhydryl-reactive Mts-Atf-Biotin and its ... to the protein interaction tool chest that ...
... a compact benchtop and stackable multi-function ... with a large display screen to ... Air circulation inside to evenly distribute ... be easily calibrated from the microprocessor ...
... Nonanoyl-N-methylglucamide White solid. ... be readily removed by dialysis. Useful ... ≥98% by HPLC. Absorbance (10%, ... 2 O. CMC 19 - 25 ...
...
Biology Products: